BBIO — Bridgebio Pharma Inc

Ownership history in Atle Fund Management AB  ·  18 quarters on record

This page tracks every 13F SEC filing in which Atle Fund Management AB reported a position in Bridgebio Pharma Inc (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
3.57% (2025 Q3)
Avg. % of fund
2.46%
First filed
2006 Q4
Last filed
2025 Q4
Quarters held
18
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 141,296 -33,426 -19.1% 3.45% $10.8M $76.49
2025 Q3 ADDED 174,722 +9,242 +5.6% 3.57% $963K $51.94
2025 Q2 ADDED 165,480 +14,132 +9.3% 3.06% $7.1M $43.18
2025 Q1 ADDED 151,348 +48,316 +46.9% 2.31% $5.2M $34.57
14 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Laurion Capital Management LP 3Y 7Y 3.28% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.25%
← Back to Atle Fund Management AB Holdings